Evoke Pharma Receives Notice from USPTO for GIMOTI Extending Orange Book Listings to 2036

July 9, 2025

DENVER, Colo., Jul 09, 2025 (247marketnews.com)- Evoke Pharma (NASDAQ:EVOK) received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application covering the use of GIMOTI in patients with moderate to severe symptoms of gastroparesis.

The allowed application is a continuation of U.S. Patent No. 11,517,545 and further strengthens Evoke’s intellectual property portfolio surrounding intranasal metoclopramide. Once granted, the new patent is expected to expire in December 2036, extending GIMOTI’s market exclusivity by an additional six years. Evoke intends to list the patent in the FDA’s Orange Book, extending the product’s protection beyond its existing patents.

Matt D’Onofrio, Evoke Pharma’s CEO, commented, “This new patent allowance adds meaningful value to the GIMOTI® franchise by reinforcing protection around how and in whom the therapy is used. Backed by extensive market research, GIMOTI continues to stand out as an effective non-oral treatment for a disease that can compromise the effectiveness of pills due to slowed gastric absorption of oral medications. We remain focused on maximizing GIMOTI’s potential as an effective patient-friendly treatment for diabetic gastroparesis.”

GIMOTI is the only FDA-approved, non-oral, self-administered formulation of metoclopramide, indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Non-oral delivery offers an important therapeutic alternative, as the nature of gastroparesis, especially symptoms like vomiting, can impair the absorption and effectiveness of oral medications.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (EVOK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.